Market Research Logo

Androgenic Alopecia - Pipeline Review, H2 2016

Androgenic Alopecia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia – Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Androgenic Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 4 and 1 respectively.

Androgenic Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Androgenic Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Androgenic Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Androgenic Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Androgenic Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Androgenic Alopecia (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Androgenic Alopecia (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Androgenic Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Androgenic Alopecia Overview
Therapeutics Development
Pipeline Products for Androgenic Alopecia - Overview
Androgenic Alopecia - Therapeutics under Development by Companies
Androgenic Alopecia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Androgenic Alopecia - Products under Development by Companies
Androgenic Alopecia - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Allergan Plc
Almirall SA
BiologicsMD Inc
Dong-A Socio Holdings Co Ltd
Histogen Inc
RepliCel Life Sciences Inc
RiverTown Therapeutics Inc
Samumed LLC
Sucampo Pharmaceuticals Inc
SWITCH Biotech LLC
Androgenic Alopecia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cyclosporine A + minoxidil + RT-175) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimatoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-1341 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BRM-421 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-0301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finasteride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finasteride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HGEN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCH-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RK-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-04554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Androgenic Alopecia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Androgenic Alopecia - Dormant Projects
Androgenic Alopecia - Discontinued Products
Androgenic Alopecia - Product Development Milestones
Featured News & Press Releases
Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles
Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial
Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial
Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia
Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient
Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research
Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness
Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Androgenic Alopecia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Androgenic Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2016
Androgenic Alopecia - Pipeline by Allergan Plc, H2 2016
Androgenic Alopecia - Pipeline by Almirall SA, H2 2016
Androgenic Alopecia - Pipeline by BiologicsMD Inc, H2 2016
Androgenic Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
Androgenic Alopecia - Pipeline by Histogen Inc, H2 2016
Androgenic Alopecia - Pipeline by RepliCel Life Sciences Inc, H2 2016
Androgenic Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2016
Androgenic Alopecia - Pipeline by Samumed LLC, H2 2016
Androgenic Alopecia - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016
Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Androgenic Alopecia - Dormant Projects, H2 2016
Androgenic Alopecia - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Androgenic Alopecia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report